secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0000950170-25-069826
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Therapeutics Q1 net income $7.4M; cash runway into Q1 2027; CAN-2409 BLA on track
--------------------------------------------------------------------------------

- Net income of $7.4M in Q1 2025 vs net loss of $8.2M in Q1 2024, driven by warrant liability fair value change.
- Cash and equivalents $92.2M as of March 31, 2025; expected to fund operations into Q1 2027.
- CAN-2409 phase 3 prostate cancer meets primary endpoint; BLA submission expected Q4 2026.
- CAN-2409 in borderline resectable PDAC: mOS 31.4 months vs 12.5 months control in phase 2a.
- CAN-2409 in NSCLC (ICI-progressive): mOS 21.5 months vs 9.8–11.8 months standard of care.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017025069826/0000950170-25-069826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017025069826/cadl-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-069826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer